Heart drug hope: can empagliflozin boost exercise in hypertrophic cardiomyopathy?
NCT ID NCT05182658
First seen Mar 13, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This study tests whether empagliflozin, a drug usually used for diabetes, can improve exercise ability and quality of life in people with hypertrophic cardiomyopathy (a condition where the heart muscle is abnormally thick). About 250 adults without diabetes will take either empagliflozin or a placebo daily for 12 months. The main goal is to see if the drug helps them use oxygen better during exercise and feel better day-to-day.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Medical University of Bialystok
Bialystok, Poland
-
National Institute of Cardiology
Warsaw, Poland
Conditions
Explore the condition pages connected to this study.